Automated Digital Pathology Device for High-Throughput Demand
Summary:
The NCI is seeking licensees to develop an automated digital pathology device compatible with high-throughput data analysis.
New Heterocyclic Scaffold-Based Inhibitors of the Polo-Box Domain of Polo-like Kinase 1 for the Treatment of Cancer
Summary:
The National Institutes of Health is seeking commercial partners to co-develop and/or license a heterocyclic scaffold for development of therapeutics against Plk1-dependent cancers.
Chimeric Antigen Receptors to CD22 for Treating Hematological Cancers
Description of Technology:
Chimeric antigen receptors (CARs) are hybrid proteins consisting of an antibody binding fragment fused to protein signaling domains that cause T-cells which express the CAR to become cytotoxic. Once activated, these cytotoxic T-cells can selectively eliminate the cells which they recognize via the antibody binding fragment of the CAR. Thus, by engineering a T-cell to express a CAR that is specific for a certain cell surface protein, it is possible to selectively target those cells for destruction. This promising new therapeutic approach
Enhanced Cancer Chemotherapy Using the Bioactive Peptide Recifin And Its Analogues
Summary:
NCI seeks research co-development partners and/or licensees for the development of recifin and its analogues as new chemosensitizing agents in adjunct therapies with topotecan, irinotecan and related chemotherapeutic agents.
High-Throughput Generation of Induced Pluripotent Stem Cells Carrying Antigen-Specific T Cell Receptors from Tumor Infiltrated Lymphocytes
Summary:
NCI seeks proposals from parties interested in licensing an improved method for the identification of TCRs from bulk populations of TIL for the development of cancer immunotherapies.
Human and Improved Murine Monoclonal Antibodies Against CD22
Summary:
Researchers at the NCI seek research and co-development partners and/or licensing for the development of human monoclonal antibodies and antibody-based therapeutics against CD22.
AT-3 Mouse Breast Tumor Cell Line
Summary:
NCI is seeking licensees for the AT-3 mouse breast tumor cell line.
Molecular Classification of Primary Mediastinal Large B Cell Lymphoma Using Formalin-Fixed, Paraffin-Embedded Tissue Specimens
Description of Technology:
Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive type of non-Hodgkin lymphoma that mostly occurs in people between the ages of 30-40. It accounts for 5-7% of all aggressive lymphomas. The diagnosis of PMBCL is challenging as the histological features of PMBCL overlap with diffuse large B-cell lymphoma (DLBCL), another most common type of non-Hodgkin lymphoma. Available evidence suggests that PMBCL responds much more favorably to the DA-EPOCH-R chemotherapy regimen than to the standard R-CHOP regimen used to treat DLBCL.
A Preclinical Model for Mutant Human EGFR-driven Lung Adenocarcinoma
Description of Technology:
Previously described epidermal growth factor receptor- (EGFR) driven tumor mouse models develop diffuse tumors, which are dissimilar to human lung tumor morphology and difficult to measure by CT and MRI scans. Scientists at the National Cancer Institute (NCI) have developed and characterized a genetically engineered mouse (GEM) model of human EGFR-driven tumor model (hEGFR-TL) that recapitulates the discrete lung tumor nodules similar to those found in human lung tumor morphology.
Parental A2780 Ovarian Cancer Cell Line and Derivative Cisplatin-resistant and Adriamycin-resistant A2780 Cell Lines
Description of Technology:
Ovarian cancer is one of the most common and lethal types of gynecological malignancies worldwide, accounting for approximately 295,000 new cases and 185,000 deaths annually. The high lethality rate is due to multiple reasons, including recurrence and the resistance of recurrent tumors to chemotherapy. Cell line models are crucial for preclinical cancer studies, to identify mechanisms of disease, to study drug resistance, and to screen for candidate therapeutics.